近期研究計畫：

1. 2016.08~2019.07 (科技部3年計畫 #105-2320-B-182A-009-MY3)

   ASS1於胃腸基質瘤之新穎二元性-腫瘤抑制及使用imatinib與藉PTPRK行KI去磷酸的精胺酸剝奪療法

    之協同治療靶

2. 2013.08~2016.07 (科技部3年計畫 #102-2628-B-182A-002-MY3)

    基因放大所致TRIO過度表現於黏液纖維肉瘤之綜合研究: 臨床、生物、及治療面之意涵

3.2014.01~2016.12 (長庚醫院3年計畫 #CMRPG8C0982)

    脂肪酸合成酶過度表現於imatinib-感應性及imatinib-抗性胃腸道基質瘤臨床、生物、及治療意涵

    之綜合探究

榮譽獎項:
98年行政院國科會吳大猷先生紀念獎
99年台灣病理學會-葉曙基金會最佳論文獎
 代表著作:

1. Lee JC, Huang HY.* Soft Tissue Special Issue: Giant Cell-rich Lesions of the Head and Neck. Head and neck Pathol 2019 doi.org/10.1007/s12105-019-01086-2 Review. (corresponding author)
2. Liau JY, Tsai JH, Lan J, Chen CC, Wang YH, Lee JC, Huang HY.* GNA11 joins GNAQ and GNA14 as a recurrently mutated gene in anastomosing hemangioma. Virchows Arch. 2019 Nov 9. doi: 10.1007/s00428-019-02673-y. [Epub ahead of print] (corresponding author)
3. Kao YC, Lee JC, Huang HY*. What is new about the molecular genetics in matrix-producing soft tissue tumors? -The contributions to pathogenetic understanding and diagnostic classification. Virchows Arch. 2019 Nov 7. doi: 10.1007/s00428-019-02679-6. [Epub ahead of print] Review. (corresponding author)
4. Li CF, Liu TT, Wang JC, Yu SC, Chen YY, Fang FM, Wan-Shan Li WS, Huang HY* Hydroxysteroid 11-beta dehydrogenase 1 overexpression with copy-number gain and missense mutations in primary gastrointestinal stromal tumors. J Clin Med. 2018 Nov 1;7(11). pii: E408. doi: 10.3390/jcm7110408 (SCI, 2017 IF: 5.583 , rank: 15/155 =9.68% in Medicine, general & internal, corresponding author^*).
5. Li CF, Liu TT, Chuang IC, Chen YY, Fu-Min Fang FM, Chan TC, Li WS, Huang HY*. PLCB4 copy gain and PLCß4 overexpression in primary gastrointestinal stromal tumors: integrative characterization of a lipid-catabolizing enzyme associated with worse disease-free survival. Oncotarget. 2017 Mar 21;8(12):19997-20010.(SCI, 2016 IF: 5.168, rank: 44/217 =20.3 % in Oncology, corresponding author)
6. Li CF, Liu TT, Chuang IC, Chen YY, Fu-Min Fang FM, Chan TC, Li WS, Huang HY*. PLCB4 copy gain and PLCß4 overexpression in primary gastrointestinal stromal tumors: integrative characterization of a lipid-catabolizing enzyme associated with worse disease-free survival. Oncotarget. 2017 Mar 21;8(12):19997-20010.(SCI, 2016 IF: 5.168, rank: 44/217 =20.3 % in Oncology, corresponding author)
7. Li CF, Liu TT, Chuang IC, Chen YY, Fu-Min Fang FM, Chan TC, Li WS, Huang HY*. PLCB4 copy gain and PLCß4 overexpression in primary gastrointestinal stromal tumors: integrative characterization of a lipid-catabolizing enzyme associated with worse disease-free survival. Oncotarget. 2017 Mar 21;8(12):19997-20010.(SCI, 2016 IF: 5.168, rank: 44/217 =20.3 % in Oncology, corresponding author)
8. Yuan CT, Huang WC, Lee CH, Lin MC, Lee CH, Kao YC, Huang HY, Kuo KT, Lee JC. Comprehensive Screening for MED12 Mutations in Gynecological Mesenchymal Tumors Identified Morphologically Distinctive Mixed Epithelial and Stromal Tumors. Histopathology. 2016 Dec 21. doi: 10.1111/his.13156. [Epub ahead of print] (SCI, 2016 IF: 3.523, rank: 15/79 =19.0 % in Pathology, corresponding author)
9. Yuan CT, Huang WC, Lee CH, Lin MC, Lee CH, Kao YC, Huang HY, Kuo KT, Lee JC. Comprehensive Screening for MED12 Mutations in Gynecological Mesenchymal Tumors Identified Morphologically Distinctive Mixed Epithelial and Stromal Tumors. Histopathology. 2016 Dec 21. doi: 10.1111/his.13156. [Epub ahead of print] (SCI, 2016 IF: 3.523, rank: 15/79 =19.0 % in Pathology, corresponding author)
10. Li CF, Liu TT, Chuang IC, Chen YY, Fu-Min Fang FM, Chan TC, Li WS, Huang HY*. PLCB4 copy gain and PLCß4 overexpression in primary gastrointestinal stromal tumors: integrative characterization of a lipid-catabolizing enzyme associated with worse disease-free survival. Oncotarget. 2017 Mar 21;8(12):19997-20010.(SCI, 2016 IF: 5.168, rank: 44/217 =20.3 % in Oncology, corresponding author)
11. Chuang IC, Liao KC, Huang HY, Kao YC, Li CF, Huang SC, Tsai JW, Chen KC, Lan J, Lin PC. NAB2-STAT6 gene fusion and STAT6 immunoexpression in extrathoracic solitary fibrous tumors: the association between fusion variants and locations. Pathol Int 2016 May;66(5):288-96.(SCI 2016 IF: 1.465, rank: 57/79 =72.2 % in Pathology, corresponding author)
12. Kao YC, Lin PC, Yen SL, Huang SC, Tsai JW, Li CF, Tai HC, Lan J, Chunag IC, Yu SC, Huang HY*. Clinicopathological and genetic heterogeneity of the head and neck solitary fibrous tumours: a comparative histological, immunohistochemical, and molecular study of 36 cases. Histopathology. 2016 Mar;68(4):492-501. (SCI 2016IF: 3.523, rank: 15/79 =19.0 % in Pathology, corresponding author^*)
13. Tai HC, Chuang IC, Chen TC, Li CF, Huang SC, Kao YC, Lin PC, Tsai JW, Lan J, Yu SC, Yen SL, Jung SM, Liao KC, Fang FM, Huang HY*. NAB2-STAT6 fusion types account for clinicopathological variations in solitary fibrous tumors: a correlative study of 88 cases. Mod Pathol 2015 Oct;28(10):1324-35. (SCI, 2016 IF: 5.728, rank: 4/79 =5.1 % in Pathology, corresponding author^*)
14. Kao YC, Lin PC, Yen SL, Huang SC, Tsai JW, Li CF, Tai HC, Lan J, Chunag IC, Yu SC, Huang HY*. Clinicopathological and genetic heterogeneity of the head and neck solitary fibrous tumours: a comparative histological, immunohistochemical, and molecular study of 36 cases. Histopathology. 2016 Mar;68(4):492-501. (SCI, 2014 IF: 3.453, rank: 15/75 =20.0 % in Pathology, corresponding author^*)
15. Tai HC, Chuang IC, Chen TC, Li CF, Huang SC, Kao YC, Lin PC, Tsai JW, Lan J, Yu SC, Yen SL, Jung SM, Liao KC, Fang FM, Huang HY*. NAB2-STAT6 fusion types account for clinicopathological variations in solitary fibrous tumors: a correlative study of 88 cases. Mod Pathol 2015 Oct;28(10):1324-35. (SCI, 2014 IF: 6.187, rank: 5/75 =6.7 % in Pathology, corresponding author^*)
16. Li CF, Chen LT, Lan L, Chou FF, Lin CY, Chen YY, Chen TJ, Li SH, Yu SC, Fang FM, Tai HC, Huang HY^*. AMACR amplification and overexpression in primary imatinib-naïve gastrointestinal stromal tumors: a driver of cell proliferation indicating adverse prognosis. Oncotarget  2014 Nov 30;5(22):11588-603. (SCI, 2014 IF: 6.359, rank: 21/211 =9.9 % in Oncology, corresponding author^*, 第12回日本臨床腫瘍學會最佳論文獎勵賞).
17. Li CF^#, Fang FM ^#, Kung HJ, Chen LT,Wang JW, Tsai JW, Yu SC, Wang YW, Li SH, Huang HY^*. Downregulated MTAP Expression in Myxofibrosarcoma: A Characterization of Inactivating Mechanisms, Tumor Suppressive Function, and Therapeutic Relevance. Oncotarget 2014 Nov 30;5(22):11428-41. (SCI, 2014 IF: 6.359, rank: 21/211 =9.9% in Oncology, corresponding author^*).
18. Li CF, Fang FM, J Lan, Wang JW, Kung HJ, Chen LT, TJ Chen, Li SH, Wang YW, HC Tai, Yu SC, HY Huang*. AMACR amplification in myxofibrosarcomas: a mechanism of overexpression that promotes cell proliferation with therapeutic relevance. Clin Cancer Res 2014 Dec;20(23):6141-52. (SCI, 2014 IF: 8.722, rank, 12/211=5.7 % in Oncology, corresponding author^*)
19. Kao YC, Lan J, Tai HC, Li CF, Liu KW, Tsai JW, Fang FM, Yu SC, Huang HY^*. Angiomatoid Fibrous Histiocytoma: clinicopathological and molecular characterization with emphasis on variant histomorphology. J Clin Pathol 2014 Mar;67(3):210-5. (SCI, 2014 IF: 2.915 , rank: 19/75 =25.3% in Pathology).
20. Wei YC, Lan J, Li CF, Chou FF, Li WM, Chen YY, Li SH, Fang FM, Hu TH, Yu SC, Eng HL, Uen YH, Tian YF, Wang JC, Huang HY*. HuR Cytoplasmic Expression is Associated with Increased Cyclin A Expression and Inferior Disease-Free Survival in Gastrointestinal Stromal Tumors (GISTs). Histopathology 2013 Oct;63(4):445-54 (SCI, 2014 IF: 3.453, rank: 15/75 =20.0 % in Pathology, corresponding author).
21. Huang HY, Wu WR, Wang YH, Wang JW, Fang FM, Tsai JW, Li SH, Hung HC, Yu SC, Lan J, Shiue YL, Hsing CH, Chen LT, Li CF. ASS1 as a Novel Tumor Suppressor Gene in Myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance. Clinical Cancer Research 2013 Jun 1;19(11):2861-2872. (SCI 2014 IF: 8.722, rank, 12/211=5.9 % in Oncology)
22. Tsai JW, Li CF, Kao YC, Wang JW, Fang FM, Wang YH, Wu WR, Wu LC, Hsing CH, Li SH, Yu SC, Lan J, Huang HY^*. Recurrent amplification at 7q21.2 targets CDK6 gene in primary myxofibrosarcomas and identifies CDK6 overexpression as an independent adverse prognosticator. Ann Surg Oncol 2012;19(8):2716–2725 (SCI 2014 IF: 3.930, rank: 15/198 =7.6 % in Surgery, corresponding author).
23. Li CF^#, Fang FM^#, Wang JM^#, Tzeng CC, Tai HC, Wei YC, Li SH, Lee YT, Wang YH, Yu SC, Shiue YL, Chu PYW, Wang WL, Chen LT, Huang HY*. EGFR nuclear import in gallbladder carcinoma: nuclear phosphorylated EGFR upregulates iNOS expression and confers independent prognostic impact. Ann Surg Oncol 2012 Feb;19(2):443-54. (SCI, 2014 IF: 3.930, rank: 15/198 =7.6 % in Surgery, corresponding author)
24. CF Hwang^#, HY Huang^#, CH Chen, CY Chien, YC Hsu, CF Li, FM Fang. Enhancer of Zeste Homolog 2 overexpression in nasopharyngeal carcinoma: an independent poor prognosticator that enhances cell growth. Int J Radiat Oncol 2012 Feb 1;82(2):597-604. (^#, equal contribution, SCI, 2014 IF: 4.258, rank: 12/125 =9.6% in Radiology, Nuclear Medicine, and Medical Imaging)
25. Huang HY*, LI CF, Fang FM, Tsai JW, LI SH, Lee YT, Wei HM. Prognostic Implication of Ezrin overexpression in Myxofibrosarcomas. Ann Surg Oncol 2010;17(12):3212-3219. (SCI, 2014 IF: 3.930, rank: 15/198 =7.6 % in Surgery, first and corresponding author).
26. Lee JC, Li CF, Fang FM, Wang JW, Jeng YM, Yu SC, Lin YT, Wu JM, Tsai JW, Li SH, Huang HY*. Prognostic Implication of MET Overexpression in Myxofibrosarcomas: an integrative array comparative genomic hybridization, real-time quantitative PCR, immunoblotting, and immunohistochemical analysis. Mod Pathol 2010;23(10):1379-1392. (SCI,  2014 IF: 6.187, rank: 5/75 =6.7 % in Pathology, CMRPG870751-2, corresponding author, 100年台灣病理學會-葉曙基金會最佳論文)